Draft US bill on payments to physicians imposes strict disclosure rules
This article was originally published in SRA
Executive Summary
Senators Charles Grassley (Republican - Iowa) and Herb Kohl (Democrat - Wisconsin) have reintroduced legislation that seeks to impose strict rules for disclosing financial relationships between medical device companies and doctors, including requiring the creation of a national registry of industry payments to physicians1. The Physician Payments Sunshine Act now has a lower payment disclosure threshold - namely requiring drug and device companies to publicly report the payments, consulting fees, honoraria and other “transfers” they give to doctors over $100 every year. In the previous version of the bill (S 2029), the threshold was $5002. The information would be posted on a federal website for public viewing in 2011.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.